A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab.

Abstract	Pityriasis rubra pilaris is a rare psoriasiform dermatitis. Treatment has been adopted from psoriasis protocols, with topical corticosteroids and systemic retinoids as first-line agents, followed by escalation to biologics for recalcitrant disease. We report a patient with resistant pityriasis rubra pilaris who dramatically improved with acitretin and ustekinumab, a combination not well documented in the literature. The purpose of this letter is to emphasize the potential benefit of dual therapy in patients who fail traditional pityriasis rubra pilaris treatment regimens.
Authors	Elizabeth Cook, Kendra Walker Tran, Sivaramya Kollipara, Michelle Tarbox, Russell Akin
Journal	Dermatology online journal (Dermatol Online J) Vol. 26 Issue 3 (Mar 15 2020) ISSN: 1087-2108 [Electronic] United States
PMID	32609453 (Publication Type: Case Reports, Letter)
Chemical References	Dermatologic Agents Keratolytic Agents Ustekinumab Acitretin
Topics	Acitretin (therapeutic use) Aged, 80 and over Dermatologic Agents (therapeutic use) Drug Therapy, Combination Humans Keratolytic Agents (therapeutic use) Male Pityriasis Rubra Pilaris (drug therapy) Ustekinumab (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!